Genetic Modifiers of Fetal Haemoglobin in Sickle Cell Disease

AbstractFetal haemoglobin (HbF) levels have a clinically beneficial effect on sickle cell disease (SCD). Patients with SCD demonstrate extreme variability in HbF levels (1 –30%), a large part of which is likely genetically determined. The main genetic modifier loci for HbF persistence,HBS1L-MYB,BCL11A and the β-globin gene cluster in adults also act in SCD patients. Their effects are, however, modified significantly by a disease pathology that includes a drastically shortened erythrocyte lifespan with an enhanced survival of those red blood cells that carry HbF (F cells). We propose a model of how HbF m odifier genes and disease pathology interact to shape HbF levels measured in patients. We review current knowledge on the action of these loci in SCD, their genetic architecture, and their putative functional components. At each locus, one strong candidate for a causative, functional DNA change has been proposed:Xmn1-HBG2 at the β-globin cluster,rs1427407 atBCL11A and the 3  bp deletionrs66650371 atHBS1L-MYB. These, however, explain only part of the impact of these loci and additional variants are yet to be identified. Further progress in understanding the genetic control of HbF levels requires that confounding factors inherent in SCD, such as ethnic complexity, the role of F cells and the influence of drugs, are suitably addressed. This will depend on international collaboration and on large, well-characterised patient cohorts with genome-wide single-nucleotide polymorph...
Source: Molecular Diagnosis and Therapy - Category: Molecular Biology Source Type: research